Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of chemically synthesized peptide therapeutics called Bicycles. The company's lead asset, zelenectide pevedotin (BT8009), is a Bicycle Toxin Conjugate targeting Nectin-4 in advanced solid tumors, currently in Phase 2/3 trials for urothelial and breast cancers. With a $400M market cap and $200M annual cash burn, the stock trades on clinical trial readouts, partnership deals, and runway extension events.
Bicycle generates pre-commercial revenue through upfront payments, research funding, and milestone payments from pharmaceutical partnerships that leverage its proprietary Bicycle platform for drug discovery. The company's synthetic peptide technology enables creation of molecules with antibody-like specificity but smaller size (2kDa vs 150kDa), potentially offering better tumor penetration and reduced immunogenicity. Long-term value creation depends on successful clinical development of BT8009 and pipeline assets (BT5528 for EphA2, BT1718 for MT1-MMP), followed by either commercialization or acquisition. Current negative margins reflect typical pre-revenue biotech economics with $50-60M quarterly operating expenses supporting multiple clinical trials.
BT8009 clinical trial data readouts in urothelial carcinoma and triple-negative breast cancer (Phase 2/3 enrollment and interim analyses)
Partnership announcements or expansion of existing collaborations (upfront payments, milestone achievements with Genentech or new partners)
FDA regulatory interactions including Breakthrough Therapy or Fast Track designations for lead programs
Capital raises and cash runway extensions (equity offerings, debt facilities, or non-dilutive funding)
Competitive landscape changes in Nectin-4 targeting space (enfortumab vedotin market dynamics, biosimilar threats)
Clinical trial failure risk: BT8009 must demonstrate superiority or differentiation versus enfortumab vedotin (Padcev) in Nectin-4 space, which generated $1.3B+ in 2025 sales. Failure in pivotal trials would eliminate 60-70% of company value
Platform validation risk: Bicycle technology remains unproven commercially with no approved products. Synthetic peptide stability, manufacturing scalability, and real-world efficacy versus antibody-drug conjugates are unvalidated
Regulatory pathway uncertainty: Novel modality may face unexpected FDA requirements for toxicology, immunogenicity monitoring, or manufacturing controls
Nectin-4 space crowding: Enfortumab vedotin dominance in urothelial cancer and expansion into earlier lines/combinations limits BT8009 addressable market. Biosimilars expected 2028-2030 will further compress pricing
ADC technology evolution: Next-generation antibody-drug conjugates with improved linkers and payloads may offer better efficacy/safety than Bicycle platform, particularly from Daiichi Sankyo, AstraZeneca, and Gilead Sciences
Partnership dependency: Loss of Genentech collaboration or failure to secure additional partnerships would eliminate non-dilutive funding and validate platform concerns
Cash runway pressure: With $200M annual burn and estimated $200-250M cash (based on 10.66 current ratio), company faces potential dilutive financing need in 2026-2027 absent partnership milestones
Equity dilution risk: 57% stock decline in past year suggests future capital raises will occur at depressed valuations, significantly diluting existing shareholders. At $400M market cap, a $100M raise would be 25% dilutive
Going concern risk: If BT8009 Phase 2/3 data disappoints and partnership revenue declines, company may lack sufficient capital to reach value-inflection milestones
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations as R&D spending is driven by scientific milestones rather than economic cycles. However, capital markets access for funding is highly sensitive to risk appetite, with biotech IPO and follow-on windows closing during recessions. Patient enrollment can be marginally affected by economic stress impacting healthcare access.
Rising interest rates create significant headwinds through multiple channels: (1) Higher discount rates compress NPV of distant cash flows from potential drug approvals 5-10 years out, (2) Risk-free rate competition makes speculative biotech less attractive versus bonds, (3) Reduced venture capital and crossover fund allocation to high-risk assets tightens financing availability. With 10-year yields above 4%, pre-revenue biotechs face 30-50% valuation compression versus 2020-2021 zero-rate environment. Cash holdings ($200M+ estimated) earn higher interest income but this is immaterial versus equity valuation impact.
Minimal direct credit exposure as the company has negligible debt (0.01 D/E ratio) and does not rely on credit markets for operations. However, broader credit stress impacts biotech sector through reduced M&A activity from pharmaceutical acquirers and tighter venture debt availability for runway extensions.
growth/speculative - Attracts biotech-specialized investors, venture capital crossover funds, and high-risk tolerance growth investors seeking asymmetric returns from clinical trial success. Not suitable for value or income investors given pre-revenue status and binary clinical risk. Typical holders include dedicated healthcare funds (Fidelity, T. Rowe Price biotech teams) and hedge funds with event-driven strategies around data readouts.
high - Clinical-stage oncology biotechs exhibit extreme volatility with 20-40% single-day moves on trial data. Stock has declined 57% over past year, demonstrating sector-wide derating and company-specific concerns. Beta likely 1.5-2.0x versus broader market. Options implied volatility typically 80-120% reflecting binary event risk around clinical readouts.